Jung E. Choi
Independent DirectorMs. Jung E. Choi is Chief Executive Officer at Alterome Therapeutics, Inc. Ms. Choi serves as Board of Manager of NYBC Ventures since October 2024. Jung serves as Entrepreneur-In-Residence at Third Rock Ventures, LLC since July 2023. She joined Third Rock Ventures, LLC in 2023. She served as a Director of Marea Therapeutics, Inc. She served as Chief Business and Strategy Officer of Global Blood Therapeutics, Inc. since April 2015 until April 2023. Ms. Choi has extensive transactional and operational leadership experience in the biopharmaceutical industry. During her career, Ms. Choi has led or managed over 50 transactions. From April 2014 to March 2015, she served as Senior Vice President of Corporate Development at InterMune, Inc. She served as adviser on strategy and business development at InterMune from March 2013 to April 2014. From August 2001 to August 2010, at Gilead Sciences, she held various management positions including leadership of business development, licensing and mergers and acquisition activities. During her tenure, she built and oversaw the corporate development group and played a leading role in Gilead’s numerous licensing transactions and company acquisitions. Ms. Choi served as the Senior Vice President of Corporate Development at Chimerix, Inc. from February 2011 to March 2013. Ms. Choi served as a Vice President of Bay City Capital LLC. She managed investment opportunities for Bay City Capital’s general life sciences funds. She has extensive experience in ehealth/ life sciences information management and also in strategic areas within biotechnology. Prior to joining Bay City Capital in 1999, she was an Engagement Manager at McKinsey & Company, where she consulted to biopharmaceutical companies. She serves as an Independent Director of Annexon, Inc. since June 2020. Ms. Choi served as the Director of Hepatitis Marketing, where she led the U.S. commercial launch of Hepsera for the treatment of hepatitis B virus. She has broad biopharmaceutical transactional and operational experience. She served as the Senior Director of Corporate Development at Gilead Sciences and was responsible for worldwide business development, licensing and mergers and acquisition activities for the company. Ms. Choi had played a leading role in Gilead’s numerous in-licensing and out-licensing transactions and M&A. She serves on the Board of Directors of Helios. Ms. Choi received an MBA from The Stanford University and holds a BA in Human Biology from Stanford University.
Positions
- Company NameAnnexon, Inc.Stock CodeANNXPositionIndependent DirectorColleagues
- DEDouglas E. LoveCEO, President & Director
- JLJennifer LewExecutive VP, CFO & Corporate Secretary
- TYTed YednockExecutive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board
- DRDean R. ArtisChief Scientific Officer & Executive VP
- LALinda A. FitzpatrickChief Human Resources Officer
- WDWilliam D. WaddillInterim Lead Independent Director
- PHP. Hugh WillisonMember of Scientific Advisory Board
